カテゴリー： 世界, 医療/バイオ, Market Monitor Global

世界の長時間作用型統合失調症治療薬市場予測2023-2029：経口薬、注射剤

【英語タイトル】Long-Acting Schizophrenia Drug Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料（MMG23LY8512）・商品コード：MMG23LY8512
・発行会社（調査会社）：Market Monitor Global
・発行日：2023年7月
・ページ数：117
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の長時間作用型統合失調症治療薬市場規模と予測を収録しています。・世界の長時間作用型統合失調症治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の長時間作用型統合失調症治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の長時間作用型統合失調症治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「経口薬」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

長時間作用型統合失調症治療薬のグローバル主要企業は、Johnson & Johnson、 Teva、 Eli Lilly、 Bristol Myers Squibb、 AstraZeneca、 Sumitomo Dainippon Pharma、 Allergan、 Novartis、 Cardinal Health、 Sun Pharmaceutical Industries、 GlaxoSmithKline、 Sanis Health、 Qilu Pharmaceutical、 Otsuka Pharmaceutical、 Vanda Pharmaceuticals、 H.Lundbeck、 Organon、 Hansoh、 Hengrui、 Nhwa Group、 Yangtze River Pharmaceutical Groupなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、長時間作用型統合失調症治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の長時間作用型統合失調症治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の長時間作用型統合失調症治療薬市場：タイプ別市場シェア、2022年
・経口薬、注射剤

世界の長時間作用型統合失調症治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の長時間作用型統合失調症治療薬市場：用途別市場シェア、2022年
・病院、薬局、その他

世界の長時間作用型統合失調症治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の長時間作用型統合失調症治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における長時間作用型統合失調症治療薬のグローバル売上、2018年-2023年
・主要企業における長時間作用型統合失調症治療薬のグローバル売上シェア、2022年
・主要企業における長時間作用型統合失調症治療薬のグローバル販売量、2018年-2023年
・主要企業における長時間作用型統合失調症治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Johnson & Johnson、 Teva、 Eli Lilly、 Bristol Myers Squibb、 AstraZeneca、 Sumitomo Dainippon Pharma、 Allergan、 Novartis、 Cardinal Health、 Sun Pharmaceutical Industries、 GlaxoSmithKline、 Sanis Health、 Qilu Pharmaceutical、 Otsuka Pharmaceutical、 Vanda Pharmaceuticals、 H.Lundbeck、 Organon、 Hansoh、 Hengrui、 Nhwa Group、 Yangtze River Pharmaceutical Group

*************************************************************

・調査・分析レポートの概要
長時間作用型統合失調症治療薬市場の定義
市場セグメント
世界の長時間作用型統合失調症治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の長時間作用型統合失調症治療薬市場規模
世界の長時間作用型統合失調症治療薬市場規模：2022年 VS 2029年
世界の長時間作用型統合失調症治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの長時間作用型統合失調症治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の長時間作用型統合失調症治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：経口薬、注射剤
長時間作用型統合失調症治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、薬局、その他
長時間作用型統合失調症治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別長時間作用型統合失調症治療薬市場規模 2022年と2029年
地域別長時間作用型統合失調症治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Johnson & Johnson、 Teva、 Eli Lilly、 Bristol Myers Squibb、 AstraZeneca、 Sumitomo Dainippon Pharma、 Allergan、 Novartis、 Cardinal Health、 Sun Pharmaceutical Industries、 GlaxoSmithKline、 Sanis Health、 Qilu Pharmaceutical、 Otsuka Pharmaceutical、 Vanda Pharmaceuticals、 H.Lundbeck、 Organon、 Hansoh、 Hengrui、 Nhwa Group、 Yangtze River Pharmaceutical Group
...

Second-generation antipsychotics are serotonin-dopamine antagonists and are also known as atypical antipsychotics.
This report aims to provide a comprehensive presentation of the global market for Long-Acting Schizophrenia Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Schizophrenia Drug. This report contains market size and forecasts of Long-Acting Schizophrenia Drug in global, including the following market information:
Global Long-Acting Schizophrenia Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Long-Acting Schizophrenia Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Oral Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Long-Acting Schizophrenia Drug include Johnson & Johnson, Teva, Eli Lilly, Bristol Myers Squibb, AstraZeneca, Sumitomo Dainippon Pharma, Allergan, Novartis and Cardinal Health, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Long-Acting Schizophrenia Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Long-Acting Schizophrenia Drug Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Long-Acting Schizophrenia Drug Market Segment Percentages, by Type, 2022 (%)
Oral
Injection
Global Long-Acting Schizophrenia Drug Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Long-Acting Schizophrenia Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Pharmacies
Other
Global Long-Acting Schizophrenia Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Long-Acting Schizophrenia Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Long-Acting Schizophrenia Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Long-Acting Schizophrenia Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Johnson & Johnson
Teva
Eli Lilly
Bristol Myers Squibb
AstraZeneca
Sumitomo Dainippon Pharma
Allergan
Novartis
Cardinal Health
Sun Pharmaceutical Industries
GlaxoSmithKline
Sanis Health
Qilu Pharmaceutical
Otsuka Pharmaceutical
Vanda Pharmaceuticals
H.Lundbeck
Organon
Hansoh
Hengrui
Nhwa Group
Yangtze River Pharmaceutical Group
Outline of Major Chapters:
Chapter 1: Introduces the definition of Long-Acting Schizophrenia Drug, market overview.
Chapter 2: Global Long-Acting Schizophrenia Drug market size in revenue.
Chapter 3: Detailed analysis of Long-Acting Schizophrenia Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Long-Acting Schizophrenia Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Long-Acting Schizophrenia Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Long-Acting Schizophrenia Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Long-Acting Schizophrenia Drug Overall Market Size
2.1 Global Long-Acting Schizophrenia Drug Market Size: 2022 VS 2029
2.2 Global Long-Acting Schizophrenia Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Long-Acting Schizophrenia Drug Players in Global Market
3.2 Top Global Long-Acting Schizophrenia Drug Companies Ranked by Revenue
3.3 Global Long-Acting Schizophrenia Drug Revenue by Companies
3.4 Top 3 and Top 5 Long-Acting Schizophrenia Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Long-Acting Schizophrenia Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Long-Acting Schizophrenia Drug Players in Global Market
3.6.1 List of Global Tier 1 Long-Acting Schizophrenia Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Long-Acting Schizophrenia Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Long-Acting Schizophrenia Drug Market Size Markets, 2022 & 2029
4.1.2 Oral
4.1.3 Injection
4.2 By Type – Global Long-Acting Schizophrenia Drug Revenue & Forecasts
4.2.1 By Type – Global Long-Acting Schizophrenia Drug Revenue, 2018-2023
4.2.2 By Type – Global Long-Acting Schizophrenia Drug Revenue, 2024-2029
4.2.3 By Type – Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Long-Acting Schizophrenia Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Pharmacies
5.1.4 Other
5.2 By Application – Global Long-Acting Schizophrenia Drug Revenue & Forecasts
5.2.1 By Application – Global Long-Acting Schizophrenia Drug Revenue, 2018-2023
5.2.2 By Application – Global Long-Acting Schizophrenia Drug Revenue, 2024-2029
5.2.3 By Application – Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Long-Acting Schizophrenia Drug Market Size, 2022 & 2029
6.2 By Region – Global Long-Acting Schizophrenia Drug Revenue & Forecasts
6.2.1 By Region – Global Long-Acting Schizophrenia Drug Revenue, 2018-2023
6.2.2 By Region – Global Long-Acting Schizophrenia Drug Revenue, 2024-2029
6.2.3 By Region – Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Long-Acting Schizophrenia Drug Revenue, 2018-2029
6.3.2 US Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.3.3 Canada Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.3.4 Mexico Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Long-Acting Schizophrenia Drug Revenue, 2018-2029
6.4.2 Germany Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.4.3 France Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.4.4 U.K. Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.4.5 Italy Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.4.6 Russia Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.4.7 Nordic Countries Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.4.8 Benelux Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Long-Acting Schizophrenia Drug Revenue, 2018-2029
6.5.2 China Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.5.3 Japan Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.5.4 South Korea Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.5.5 Southeast Asia Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.5.6 India Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Long-Acting Schizophrenia Drug Revenue, 2018-2029
6.6.2 Brazil Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.6.3 Argentina Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Long-Acting Schizophrenia Drug Revenue, 2018-2029
6.7.2 Turkey Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.7.3 Israel Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Long-Acting Schizophrenia Drug Market Size, 2018-2029
6.7.5 UAE Long-Acting Schizophrenia Drug Market Size, 2018-2029
7 Long-Acting Schizophrenia Drug Companies Profiles
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Company Summary
7.1.2 Johnson & Johnson Business Overview
7.1.3 Johnson & Johnson Long-Acting Schizophrenia Drug Major Product Offerings
7.1.4 Johnson & Johnson Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.1.5 Johnson & Johnson Key News & Latest Developments
7.2 Teva
7.2.1 Teva Company Summary
7.2.2 Teva Business Overview
7.2.3 Teva Long-Acting Schizophrenia Drug Major Product Offerings
7.2.4 Teva Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.2.5 Teva Key News & Latest Developments
7.3 Eli Lilly
7.3.1 Eli Lilly Company Summary
7.3.2 Eli Lilly Business Overview
7.3.3 Eli Lilly Long-Acting Schizophrenia Drug Major Product Offerings
7.3.4 Eli Lilly Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.3.5 Eli Lilly Key News & Latest Developments
7.4 Bristol Myers Squibb
7.4.1 Bristol Myers Squibb Company Summary
7.4.2 Bristol Myers Squibb Business Overview
7.4.3 Bristol Myers Squibb Long-Acting Schizophrenia Drug Major Product Offerings
7.4.4 Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.4.5 Bristol Myers Squibb Key News & Latest Developments
7.5 AstraZeneca
7.5.1 AstraZeneca Company Summary
7.5.2 AstraZeneca Business Overview
7.5.3 AstraZeneca Long-Acting Schizophrenia Drug Major Product Offerings
7.5.4 AstraZeneca Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.5.5 AstraZeneca Key News & Latest Developments
7.6 Sumitomo Dainippon Pharma
7.6.1 Sumitomo Dainippon Pharma Company Summary
7.6.2 Sumitomo Dainippon Pharma Business Overview
7.6.3 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Major Product Offerings
7.6.4 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.6.5 Sumitomo Dainippon Pharma Key News & Latest Developments
7.7 Allergan
7.7.1 Allergan Company Summary
7.7.2 Allergan Business Overview
7.7.3 Allergan Long-Acting Schizophrenia Drug Major Product Offerings
7.7.4 Allergan Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.7.5 Allergan Key News & Latest Developments
7.8 Novartis
7.8.1 Novartis Company Summary
7.8.2 Novartis Business Overview
7.8.3 Novartis Long-Acting Schizophrenia Drug Major Product Offerings
7.8.4 Novartis Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.8.5 Novartis Key News & Latest Developments
7.9 Cardinal Health
7.9.1 Cardinal Health Company Summary
7.9.2 Cardinal Health Business Overview
7.9.3 Cardinal Health Long-Acting Schizophrenia Drug Major Product Offerings
7.9.4 Cardinal Health Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.9.5 Cardinal Health Key News & Latest Developments
7.10 Sun Pharmaceutical Industries
7.10.1 Sun Pharmaceutical Industries Company Summary
7.10.2 Sun Pharmaceutical Industries Business Overview
7.10.3 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Major Product Offerings
7.10.4 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.10.5 Sun Pharmaceutical Industries Key News & Latest Developments
7.11 GlaxoSmithKline
7.11.1 GlaxoSmithKline Company Summary
7.11.2 GlaxoSmithKline Business Overview
7.11.3 GlaxoSmithKline Long-Acting Schizophrenia Drug Major Product Offerings
7.11.4 GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.11.5 GlaxoSmithKline Key News & Latest Developments
7.12 Sanis Health
7.12.1 Sanis Health Company Summary
7.12.2 Sanis Health Business Overview
7.12.3 Sanis Health Long-Acting Schizophrenia Drug Major Product Offerings
7.12.4 Sanis Health Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.12.5 Sanis Health Key News & Latest Developments
7.13 Qilu Pharmaceutical
7.13.1 Qilu Pharmaceutical Company Summary
7.13.2 Qilu Pharmaceutical Business Overview
7.13.3 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Major Product Offerings
7.13.4 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.13.5 Qilu Pharmaceutical Key News & Latest Developments
7.14 Otsuka Pharmaceutical
7.14.1 Otsuka Pharmaceutical Company Summary
7.14.2 Otsuka Pharmaceutical Business Overview
7.14.3 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Major Product Offerings
7.14.4 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.14.5 Otsuka Pharmaceutical Key News & Latest Developments
7.15 Vanda Pharmaceuticals
7.15.1 Vanda Pharmaceuticals Company Summary
7.15.2 Vanda Pharmaceuticals Business Overview
7.15.3 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Major Product Offerings
7.15.4 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.15.5 Vanda Pharmaceuticals Key News & Latest Developments
7.16 H.Lundbeck
7.16.1 H.Lundbeck Company Summary
7.16.2 H.Lundbeck Business Overview
7.16.3 H.Lundbeck Long-Acting Schizophrenia Drug Major Product Offerings
7.16.4 H.Lundbeck Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.16.5 H.Lundbeck Key News & Latest Developments
7.17 Organon
7.17.1 Organon Company Summary
7.17.2 Organon Business Overview
7.17.3 Organon Long-Acting Schizophrenia Drug Major Product Offerings
7.17.4 Organon Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.17.5 Organon Key News & Latest Developments
7.18 Hansoh
7.18.1 Hansoh Company Summary
7.18.2 Hansoh Business Overview
7.18.3 Hansoh Long-Acting Schizophrenia Drug Major Product Offerings
7.18.4 Hansoh Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.18.5 Hansoh Key News & Latest Developments
7.19 Hengrui
7.19.1 Hengrui Company Summary
7.19.2 Hengrui Business Overview
7.19.3 Hengrui Long-Acting Schizophrenia Drug Major Product Offerings
7.19.4 Hengrui Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.19.5 Hengrui Key News & Latest Developments
7.20 Nhwa Group
7.20.1 Nhwa Group Company Summary
7.20.2 Nhwa Group Business Overview
7.20.3 Nhwa Group Long-Acting Schizophrenia Drug Major Product Offerings
7.20.4 Nhwa Group Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.20.5 Nhwa Group Key News & Latest Developments
7.21 Yangtze River Pharmaceutical Group
7.21.1 Yangtze River Pharmaceutical Group Company Summary
7.21.2 Yangtze River Pharmaceutical Group Business Overview
7.21.3 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Major Product Offerings
7.21.4 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue in Global Market (2018-2023)
7.21.5 Yangtze River Pharmaceutical Group Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Long-Acting Schizophrenia Drug Market Opportunities & Trends in Global Market
Table 2. Long-Acting Schizophrenia Drug Market Drivers in Global Market
Table 3. Long-Acting Schizophrenia Drug Market Restraints in Global Market
Table 4. Key Players of Long-Acting Schizophrenia Drug in Global Market
Table 5. Top Long-Acting Schizophrenia Drug Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Long-Acting Schizophrenia Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Long-Acting Schizophrenia Drug Revenue Share by Companies, 2018-2023
Table 8. Global Companies Long-Acting Schizophrenia Drug Product Type
Table 9. List of Global Tier 1 Long-Acting Schizophrenia Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Long-Acting Schizophrenia Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Long-Acting Schizophrenia Drug Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Long-Acting Schizophrenia Drug Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Long-Acting Schizophrenia Drug Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Long-Acting Schizophrenia Drug Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Long-Acting Schizophrenia Drug Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Long-Acting Schizophrenia Drug Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2024-2029
Table 30. Johnson & Johnson Company Summary
Table 31. Johnson & Johnson Long-Acting Schizophrenia Drug Product Offerings
Table 32. Johnson & Johnson Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 33. Johnson & Johnson Key News & Latest Developments
Table 34. Teva Company Summary
Table 35. Teva Long-Acting Schizophrenia Drug Product Offerings
Table 36. Teva Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 37. Teva Key News & Latest Developments
Table 38. Eli Lilly Company Summary
Table 39. Eli Lilly Long-Acting Schizophrenia Drug Product Offerings
Table 40. Eli Lilly Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 41. Eli Lilly Key News & Latest Developments
Table 42. Bristol Myers Squibb Company Summary
Table 43. Bristol Myers Squibb Long-Acting Schizophrenia Drug Product Offerings
Table 44. Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 45. Bristol Myers Squibb Key News & Latest Developments
Table 46. AstraZeneca Company Summary
Table 47. AstraZeneca Long-Acting Schizophrenia Drug Product Offerings
Table 48. AstraZeneca Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 49. AstraZeneca Key News & Latest Developments
Table 50. Sumitomo Dainippon Pharma Company Summary
Table 51. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Product Offerings
Table 52. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 53. Sumitomo Dainippon Pharma Key News & Latest Developments
Table 54. Allergan Company Summary
Table 55. Allergan Long-Acting Schizophrenia Drug Product Offerings
Table 56. Allergan Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 57. Allergan Key News & Latest Developments
Table 58. Novartis Company Summary
Table 59. Novartis Long-Acting Schizophrenia Drug Product Offerings
Table 60. Novartis Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 61. Novartis Key News & Latest Developments
Table 62. Cardinal Health Company Summary
Table 63. Cardinal Health Long-Acting Schizophrenia Drug Product Offerings
Table 64. Cardinal Health Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 65. Cardinal Health Key News & Latest Developments
Table 66. Sun Pharmaceutical Industries Company Summary
Table 67. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Product Offerings
Table 68. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 69. Sun Pharmaceutical Industries Key News & Latest Developments
Table 70. GlaxoSmithKline Company Summary
Table 71. GlaxoSmithKline Long-Acting Schizophrenia Drug Product Offerings
Table 72. GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 73. GlaxoSmithKline Key News & Latest Developments
Table 74. Sanis Health Company Summary
Table 75. Sanis Health Long-Acting Schizophrenia Drug Product Offerings
Table 76. Sanis Health Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 77. Sanis Health Key News & Latest Developments
Table 78. Qilu Pharmaceutical Company Summary
Table 79. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Product Offerings
Table 80. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 81. Qilu Pharmaceutical Key News & Latest Developments
Table 82. Otsuka Pharmaceutical Company Summary
Table 83. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Product Offerings
Table 84. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 85. Otsuka Pharmaceutical Key News & Latest Developments
Table 86. Vanda Pharmaceuticals Company Summary
Table 87. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Product Offerings
Table 88. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 89. Vanda Pharmaceuticals Key News & Latest Developments
Table 90. H.Lundbeck Company Summary
Table 91. H.Lundbeck Long-Acting Schizophrenia Drug Product Offerings
Table 92. H.Lundbeck Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 93. H.Lundbeck Key News & Latest Developments
Table 94. Organon Company Summary
Table 95. Organon Long-Acting Schizophrenia Drug Product Offerings
Table 96. Organon Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 97. Organon Key News & Latest Developments
Table 98. Hansoh Company Summary
Table 99. Hansoh Long-Acting Schizophrenia Drug Product Offerings
Table 100. Hansoh Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 101. Hansoh Key News & Latest Developments
Table 102. Hengrui Company Summary
Table 103. Hengrui Long-Acting Schizophrenia Drug Product Offerings
Table 104. Hengrui Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 105. Hengrui Key News & Latest Developments
Table 106. Nhwa Group Company Summary
Table 107. Nhwa Group Long-Acting Schizophrenia Drug Product Offerings
Table 108. Nhwa Group Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 109. Nhwa Group Key News & Latest Developments
Table 110. Yangtze River Pharmaceutical Group Company Summary
Table 111. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Product Offerings
Table 112. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue (US$, Mn) & (2018-2023)
Table 113. Yangtze River Pharmaceutical Group Key News & Latest Developments
List of Figures
Figure 1. Long-Acting Schizophrenia Drug Segment by Type in 2022
Figure 2. Long-Acting Schizophrenia Drug Segment by Application in 2022
Figure 3. Global Long-Acting Schizophrenia Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Long-Acting Schizophrenia Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Long-Acting Schizophrenia Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Long-Acting Schizophrenia Drug Revenue in 2022
Figure 8. By Type - Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
Figure 9. By Application - Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
Figure 10. By Type - Global Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
Figure 12. By Application - Global Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
Figure 14. By Region - Global Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
Figure 15. By Country - North America Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
Figure 16. US Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
Figure 20. Germany Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 21. France Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
Figure 28. China Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 32. India Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
Figure 34. Brazil Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Long-Acting Schizophrenia Drug Revenue Market Share, 2018-2029
Figure 37. Turkey Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Long-Acting Schizophrenia Drug Revenue, (US$, Mn), 2018-2029
Figure 41. Johnson & Johnson Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Teva Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Eli Lilly Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. AstraZeneca Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Allergan Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Novartis Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Cardinal Health Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Sanis Health Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. H.Lundbeck Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Organon Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Hansoh Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. Hengrui Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 60. Nhwa Group Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 61. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



★調査レポート[世界の長時間作用型統合失調症治療薬市場予測2023-2029：経口薬、注射剤] (コード：MMG23LY8512)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の長時間作用型統合失調症治療薬市場予測2023-2029：経口薬、注射剤]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の慢性疲労症候群治療薬市場予測2023-2029：鎮痛剤・NSAID、抗うつ薬・抗精神病薬、抗菌薬・免疫調節薬
  • 世界の避妊薬市場予測2023-2029：経口避妊薬、避妊注射薬、局所避妊パッチ
  • 世界のストレス管理薬市場予測2023-2029：抗うつ薬、非定型抗精神病薬、ベンゾジアゼピン系医薬品
  • 世界の動物用医薬品市場予測2023-2029：経口、注射、その他
  • 世界の性腺機能低下症治療薬市場予測2023-2029：注射剤、カプセル剤

    • ◆H&Iグローバルリサーチのお客様（例）◆